![Mesoglycan for the secondary prevention of superficial vein thrombosis: a randomized, controlled, double-blind study (METRO Study)—rationale and protocol | Journal of Thrombosis and Thrombolysis Mesoglycan for the secondary prevention of superficial vein thrombosis: a randomized, controlled, double-blind study (METRO Study)—rationale and protocol | Journal of Thrombosis and Thrombolysis](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs11239-023-02896-6/MediaObjects/11239_2023_2896_Fig1_HTML.png)
Mesoglycan for the secondary prevention of superficial vein thrombosis: a randomized, controlled, double-blind study (METRO Study)—rationale and protocol | Journal of Thrombosis and Thrombolysis
Foglio illustrativo: informazioni per il paziente Prisma 24 mg capsule rigide Prisma 50 mg capsule rigide Mesoglicano Legga atte
![PDF) Mesoglycan for the secondary prevention of superficial vein thrombosis: a randomized, controlled, double-blind study (METRO Study)—rationale and protocol PDF) Mesoglycan for the secondary prevention of superficial vein thrombosis: a randomized, controlled, double-blind study (METRO Study)—rationale and protocol](https://www.researchgate.net/publication/375418331/figure/fig1/AS:11431281203409339@1699326755167/Flow-of-the-patients-through-the-study_Q320.jpg)
PDF) Mesoglycan for the secondary prevention of superficial vein thrombosis: a randomized, controlled, double-blind study (METRO Study)—rationale and protocol
![Prisma®: indicazioni, posologia, utilizzo in gravidanza del Mesoglicano Sodico. Quotidiano Sanitario AssoCareNews.it Prisma®: indicazioni, posologia, utilizzo in gravidanza del Mesoglicano Sodico. Quotidiano Sanitario AssoCareNews.it](https://www.assocarenews.it/wp/wp-content/uploads/2022/12/LogoACN-2023-AssoCareNewsFINE-150x150.png)